About Bluejay Therapeutics Bluejay Therapeutics is a clinical-stage biopharmaceutical company focused on the development of potentially life-changing treatments for viral hepatitis and liver diseases.
Hepatitis D can lead to a host of devastating symptoms and is the most severe form of viral hepatitis. “It's much more ...
GlobalData on MSN10h
Precision gains CTA approval in Hong Kong for chronic hepatitis B therapy trialWith its compact design and precision cutting capabilities, PBGENE-HBV specifically targets a highly conserved sequence ...
In 2023, there were an estimated 68,890 people living with hepatitis C in Australia, down 58% from 162,590 at the end of 2015 ...
However, the combination of Merck's approved doravirine and investigational islatravir didn't prove superiority over Gilead's ...
Chronic hepatitis D (CHD) is the most severe form of viral hepatitis, carrying a greater risk of developing cirrhosis and its ...
Press Release - Egypt's Hepatitis Programme, also known as the "100 Million Healthier Lives" campaign has become a benchmark for African countries. The nationwide effort has led the country to become ...
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that tobevibart and elebsiran have received U.S. Food and Drug ...
report_id=bwcc17894 Hepatitis C is a viral illness that can result in significant liver damage by inflaming the liver. Contaminated blood can spread the hepatitis C virus (HCV). Tests for viral load, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback